Vitreoretinal Surgery for Severe Retinal Capillary Hemangiomas in Von Hippel-Lindau Disease

被引:50
作者
Gaudric, Alain [1 ,2 ]
Krivosic, Valerie [2 ]
Duguid, Graham [3 ]
Massin, Pascale [2 ]
Giraud, Sophie [4 ]
Richard, Stephane [5 ,6 ,7 ]
机构
[1] Hop Lariboisiere, AP HP, Serv Ophtalmol, Ctr Reference Malad Vasc Rares Cerveau & Aeil, F-75010 Paris, France
[2] Univ Paris 07, Serv Ophthalmol, Hop Lariboisiere, AP HP, Paris, France
[3] Western Eye Hosp, London, England
[4] Hosp Civils Lyon, Serv Genet Mol & Clin, Hop E Herriot, Lyon, France
[5] Fac Med Paris Sud, CNRS, EPHE FRE 2939, Le Kremlin Bicetre, France
[6] Inst Cancerol Gustave Roussy, Villejuif, France
[7] Hop Bicetre, AP HP, Ctr Reference Canc Rares INCa Malad VHL & Predisp, Serv Urol, Le Kremlin Bicetre, France
关键词
RECEPTOR INHIBITOR SU5416; PARS-PLANA VITRECTOMY; PHOTODYNAMIC THERAPY; MACULAR DETACHMENT; HEMANGIOBLASTOMAS; ANGIOMA; VERTEPORFIN; RESECTION;
D O I
10.1016/j.ophtha.2010.04.031
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate the long-term success rate of vitreoretinal surgery for severe cases of retinal capillary hemangiomas (RCHs) caused by von Hippel-Lindau (VHL) disease. Design: Retrospective case series. Participants: Twenty-three eyes of 21 patients with severe exudative or tractional retinal detachment caused by RCH, who had undergone vitreoretinal surgery. Patients' age at initial surgery ranged from 12 to 47 years (median, 27 years), and the fellow eye was already blind in 6 of 21 patients. Interventions: All eyes underwent pars plana vitrectomy with posterior hyaloid detachment epiretinal membrane dissection and silicone oil or gas injection. In 9 eyes, retinectomy was performed to remove the RCH (group R). In the other 14 eyes, the RCH was treated by laser endophotocoagulation alone or combined with transscleral cryotherapy (group L). Main Outcome Measures: Visual acuity (preoperative, 6 and 18 months postoperatively), rate of RCH recurrence, and postoperative complications. Results: In group R, an average of 2 operations per patient was needed. Six months after surgery, the retina was flat in 8 eyes. Mean follow-up was 8 years. Long-term complications included RCH reproliferation and neovascular glaucoma in 4 eyes, 4 to 8 years after initial surgery. In the remaining 5 eyes, visual acuity ranged from 20/320 to counting fingers 18 months postoperatively. In group L, an average of 1.7 operations was needed. Six months after surgery, the retina was flat in 13 of 14 eyes. Mean follow-up was 4 years. New RCH occurred in 10 eyes and required laser treatment. In the long term, 1 eye became blind after 5 years because of aggressive RCH reproliferation and neovascular glaucoma, and 2 eyes became blind after 10 years because of exudative retinal detachment. In the 11 remaining eyes, visual acuity ranged from 20/320 to 20/20 (median: 20/50) 18 months postoperatively. Conclusions: Vitreoretinal surgery is an effective treatment for severe VHL retinal hemangiomas. Large RCHs were satisfactorily treated by (1) vitrectomy with epiretinal dissection and endolaser photocoagulation or (2) retinectomy for RCH resection, although a high rate of vision-threatening RCH recurrence was observed in the long term. However in most cases, surgery improved or prolonged visual function in these eyes.
引用
收藏
页码:142 / 149
页数:8
相关论文
共 33 条
[1]   Three cases of large retinal capillary hemangiomas treated with verteporfin and photodynamic therapy [J].
Aaberg, TM ;
Aaberg, TM ;
Martin, DF ;
Gilman, JP ;
Myles, R .
ARCHIVES OF OPHTHALMOLOGY, 2005, 123 (03) :328-332
[2]   Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelia growth factor receptor inhibitor SU5416 [J].
Aiello, LP ;
George, DJ ;
Cahill, MT ;
Wong, JS ;
Cavallerano, J ;
Hannah, AL ;
Kaelin, WG .
OPHTHALMOLOGY, 2002, 109 (09) :1745-1751
[3]   Retinal capillary hemangioma treated with verteporfin photodynamic therapy [J].
Atebara, NH .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2002, 134 (05) :788-790
[4]   Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced Von Hippel-Lindau disease of the retina [J].
Dahr, Sam S. ;
Cusick, Michael ;
Rodriguez-Coleman, Hanna ;
Srivastava, Sunil K. ;
Thompson, Darby J. ;
Linehan, W. Marston ;
Ferris, Frederick L., III ;
Chew, Emily Y. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2007, 27 (02) :150-158
[5]   Use of intravitreal bevacizumab in a patient with a Von Hippel-Lindau-associated retinal haemangioblastoma of the optic nerve head: A case report [J].
de Klerk T.A. ;
Steel D.H.W. .
Journal of Medical Case Reports, 2 (1)
[6]  
Dollfus H, 2002, INVEST OPHTH VIS SCI, V43, P3067
[7]   Transretinal Feeder vessel ligature in von Hippel-Lindau disease [J].
Farah, ME ;
Uno, F ;
Höfling-Lima, AL ;
Morales, PH ;
Costa, RA ;
Cardillo, JA .
EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2001, 11 (04) :386-388
[8]   Therapeutic options for capillary papillary hemangiomas [J].
Garcia-Arumí, J ;
Sararols, LH ;
Cavero, L ;
Escalada, F ;
Corcóstegui, BF .
OPHTHALMOLOGY, 2000, 107 (01) :48-54
[9]  
Gaudric A, 1987, Bull Soc Ophtalmol Fr, V87, P1357
[10]   Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas [J].
Girmens, JF ;
Erginay, A ;
Massin, P ;
Scigalla, P ;
Gaudric, A ;
Richard, S .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2003, 136 (01) :194-196